Welcome to our dedicated page for Ngm Biopharmaceuticals news (Ticker: NGM), a resource for investors and traders seeking the latest updates and insights on Ngm Biopharmaceuticals stock.
NGM Biopharmaceuticals (NGM) is a clinical-stage biopharmaceutical company pioneering novel biologic therapies through its integrated drug discovery platform. This page serves as the definitive source for verified updates on the company's research advancements, clinical developments, and strategic milestones.
Investors and industry professionals will find timely updates across key areas including clinical trial progress, regulatory filings, partnership announcements, and financial reporting. Our curated collection ensures access to primary-source materials while maintaining compliance with financial disclosure standards.
The news archive features categorized updates on therapeutic developments in NGM's core focus domains: cardio-metabolic disorders, liver diseases, and emerging oncology programs. Each entry connects to the company's biology-driven approach, emphasizing its protein engineering capabilities and target validation methodologies.
For consistent monitoring of NGM's innovative pipeline, bookmark this page or check back regularly. Subscribers to our financial updates service receive automated alerts when new material disclosures are published.
NGM Biopharmaceuticals, Inc. (NGM), a biotechnology firm, announced CEO David J. Woodhouse will join the Cowen 43rd Annual Health Care Conference on March 7 at 9:10 am ET. He will discuss NGM's wholly-owned oncology portfolio as part of the Novel Oncology Targets Panel.
A live webcast will be available on NGM’s website, with a replay accessible for 30 days post-event. NGM focuses on developing transformative therapies, with a portfolio that includes four solid tumor oncology programs currently in clinical development.
NGM Biopharmaceuticals, Inc. (NGM) provided highlights and financial results for Q4 and full year 2022 on February 28, 2023. The company presented promising preliminary findings for NGM707 during the ESMO I-O Congress, showing early anti-tumor activity in advanced solid tumors. They initiated a Phase 1b trial for NGM438 in combination with KEYTRUDA. For 2022, NGM reported a net loss of $162.7 million, up from $120.3 million in 2021. R&D expenses rose to $181.1 million, while related party revenue from Merck decreased to $55.3 million. As of December 31, 2022, NGM had cash reserves of $271.5 million.
NGM Biopharmaceuticals, Inc. (NGM) will participate in the B. Riley Securities 3rd Annual Oncology Conference on January 19, 2023, at 11:00 am ET. CEO David J. Woodhouse, Ph.D., and CFO Siobhan Nolan Mangini will provide a business update focusing on NGM's oncology portfolio. A live webcast of the event will be available on NGM's website, and a replay will be accessible for 30 days post-event. NGM is dedicated to developing transformative therapeutics through biology-centric drug discovery, currently advancing five clinical programs.
NGM Biopharmaceuticals (NGM) provided an overview of its 2022 highlights and 2023 priorities. The three-pronged strategy emphasizes clinical development in solid tumor oncology, generating next-generation biologics, and forming partnerships for various programs, including aldafermin and NGM621. Notably, the company aims to advance its myeloid checkpoint inhibitor programs, NGM707, NGM831, and NGM438, into further clinical trials in 2023. NGM Bio's cash resources are projected to fund operations into Q4 2024, supporting its focus on developing transformative therapeutics.
